Hepatitis C virus (HCV) infections lead to liver cirrhosis and hepatocellular carcinoma. Currently no efficient drug or vaccine is available. A team of 6 European laboratories from D, F, PL will synthesise and investigate the psycho-chemical and biological properties of a broad range of new modified nucleoside derivatives, guanine, trampoline and anthracycline analogy and their prod rugs, potential inhibitors of HCV RNA helices, a novel and promising target for anti- HCV therapy. The interactions of analogy with HCV helices will be investigated with the use of kinetic methods, crystallography, and multidimensional NMR and CD spectroscopy. Inhibitory activity against HCV helices will be verified in vitro in HCV-infected human macrophages, in human hepatocytes and in yeast cell system. This research should deliver new anti-HCV drugs and may improve the quality of life of millions of HCV-infected patients.
Funding SchemeCSC - Cost-sharing contracts
43 200 Pszczyna
02 106 Warszawa